Related references
Note: Only part of the references are listed.Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
John N. Allan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors
Eric Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E. Ahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib
Adam S. Kittai et al.
BLOOD (2021)
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Paul M. Barr et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Jennifer Woyach et al.
LEUKEMIA & LYMPHOMA (2021)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Graeme A. M. Fraser et al.
LEUKEMIA & LYMPHOMA (2020)
Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
Inhye E. Ahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Ibrutinib Induces Durable Remissions in Treatment-Naive CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study
Mariela Sivina et al.
BLOOD (2020)
Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy
Alankrita Taneja et al.
LEUKEMIA & LYMPHOMA (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
Jennifer Woyach et al.
BLOOD (2019)
BTK Leu528Trp-a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
Sasanka M. Handunnetti et al.
BLOOD (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
F. Nadeu et al.
LEUKEMIA (2018)
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Inhye E. Ahn et al.
BLOOD (2018)
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism
Jiaji G. Chen et al.
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies
Allard Kaptein et al.
BLOOD (2018)
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL
Sabah Kadri et al.
BLOOD ADVANCES (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Share Paper
